Info@prismmediawire.com
646-780-8850
Get started

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.

Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025
Dates: February 11-12, 2025
Location: Snowbird, Utah, USA

About Oncocyte

Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney is a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA (dd-cfDNA) following kidney transplantation.

VitaGraft Kidney™ – https://oncocyte.com/vitagraft-kidney/

VitaGraft Liver is a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA (dd-cfDNA) following liver transplantation.

VitaGraft Liver™ – https://oncocyte.com/vitagraft-liver/

GraftAssure is a dd-cfDNA test that uses droplet digital PCR (dPCR) technology to measure the concentration of dd-cfDNA using 48 predefined SNPs with high minor allele population frequency. The kit enables the determination of both fractional (%) and absolute (copies/mL) concentration of dd-cfDNA for a comprehensive understanding of the amount of dd-cfDNA in the sample.

GraftAssure™ – https://oncocyte.com/graftassure/

DetermaIO is a novel gene expression assay that measures expression levels of 27-genes to assess various components of the tumor immune microenvironment (TIME). The test has been shown to identify patients that are likely to benefit from immune checkpoint inhibitor (ICI) therapy.​

DetermaIO™ – https://oncocyte.com/determa-io/

DetermaIO is a novel gene expression assay that measures expression levels of 27-genes to assess various components of the tumor immune microenvironment (TIME). The test has been shown to identify patients that are likely to benefit from immune checkpoint inhibitor (ICI) therapy.​

DetermaCNI™ – https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:

Jeff Ramson
 PCG Advisory
 (646) 863-6893
jramson@pcgadvisory.com

Source: Oncocyte